関連する実験動画
Updated: Jul 11, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
膀バイネシス:インスリン分泌膀に対するグルコースの影響
まとめ
ベータ細胞の膜プロセスである膀バイネシスは,グルコース刺激により増加します. これは,膀がインスリン放出に積極的に参加していることを示唆しています.
科学分野:
- 細胞生物学 細胞生物学
- エンドクリノロジー エンドクリノロジー
- 糖尿病に関する研究
背景:
- 臓のβ細胞からのインスリン分泌は,グルコースホメオスタシスにとって極めて重要です.
- インスリン膀の放出の正確なメカニズムはまだ調査中です.
研究 の 目的:
- 臓のβ細胞における膀のバイネシス現象を調査する.
- 膀性バイネシスに対するグルコース濃度の影響を測定する.
- インスリン放出における膀膜の変化の役割を調査する.
主な方法:
- 臓のβ細胞形態の観察.
- ランゲルハンスの小島を様々なグルコース濃度で化.
- 膀膜構造の顕微鏡分析.
主要な成果:
- 隣接する膀をインデントするインスリン分泌膀膜のリンギュラ形成であるビネシスが観察されました.
- 膀バイネシスは,小島が刺激性グルコース濃度 (300 mg/dL) でインキュブされたときに有意に増加した.
結論:
- 膀バイネシスは,インスリン分泌膀の活性化に関連した形態学的変化を表します.
- 膀膜は,インスリン放出機構において活発な役割を果たします.
関連する概念動画
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

